NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-08-31
Reading MRK? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Non-GAAP EPS at least $5.04 in 2026: FY26 EPS guidance $2.71 vs $5.04 target.
Merck grows revenue about 4.3% next year. Profit per share is guided near $5.10. New cancer drug approvals boost future sales. The company raised revenue and profit forecasts recently.
Legal investigations in China could hurt Merck's reputation. This may slow growth. Profit guidance is mixed despite recent raises.
The price is about 27% above our fair value near $101. Analysts expect 4% revenue growth. Our fair value is below the Street's median of $146.
Breaks if: EPS falls below $5.04 in FY26
Breaks if: Material penalties or operational disruptions from China investigations
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on oncology and steady revenue growth. The current thesis is intact, but confidence has shifted to medium due to mixed signals in guidance and recent earnings trends.
The market currently prices MRK at an expensive valuation compared to its peers, reflecting high expectations for future performance. There is a significant expectations gap, indicating that the market anticipates continued strong results.
Fundamentals are likely to remain robust, driven by ongoing sales growth in oncology and management's commitment to advancing their pipeline. However, there is a moderate risk due to mixed guidance on non-GAAP EPS and the potential for earnings surprises.
The thesis hinges on MRK's ability to maintain credibility with its guidance and the overall performance of the healthcare sector. Key indicators include the earnings results of sector bellwethers and the impact of economic conditions on healthcare spending.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Merck raised its full-year non-GAAP EPS guidance, indicating stronger financial performance. The oncology pipeline is advancing, which adds to growth expectations. There are no current threats to this improved outlook.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No significant oncology approvals or pipeline advances in 12 months
Breaks if: Revenue falls below $65.8 billion in FY26
In the next 1 to 3 years, MRK's performance will depend on its execution in oncology and sector dynamics. Not investment advice.
